1 / 19

Febr uary 2012

Febr uary 2012. Forward-looking Statements.

clodia
Télécharger la présentation

Febr uary 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. February 2012

  2. Forward-looking Statements Information contained in this presentation may contain forward-looking statements, including, but not limited to: the expectation that Easy Check and GlucoChip will eliminate the patient’s need to prick his/her finger multiple times per day, the expectation that GlucoChip will have a one-year life span, that the product launch of iglucose is expected by early 2012, and the development timeline provided for iglucose, Easy Check and GlucoChip. These forward-looking statements are not statements of historical fact and represent only PositiveID Corporation's beliefs regarding future performance, which is inherently uncertain. There are a variety of factors, many of which are beyond the control of PositiveID Corporation, which affect operations, performance, business strategy and results and could cause actual results and experience to differ materially from the expectations and objectives expressed in any forward-looking statements. Additional information about these and other factors that could affect PositiveID Corporation's business is set forth in PositiveID Corporation's various filings with the Securities and Exchange Commission, including those set forth in PositiveID Corporation's Form 10-K filed on March 25, 2011, and Forms 10-Q filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption “Risk Factors.” PositiveID Corporation undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law. 2

  3. Key Facts 3

  4. PositiveID Summary • PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection products. • It’s key products are: • iglucose – automatic wireless communication of blood sugar readings • Easy Check – non-invasive breath detection of glucose levels • GlucoChip – implantable RFID glucose-sensing microchip • M-BAND – sample processing and detection of airborne bio-threats • Dragonfly – disposable cartridge for biological sample processing and detection (rapid PCR) for biodefense and clinical applications 4

  5. TM • Easy-to-use, patent-pending wireless device that connects and communicates automatically from existing data-capable glucometers • FDA clearance received November 2011 • Collects, records and transmits a patient’s blood glucose data from a glucometer to the iglucose online database • iglucose correlates data and sends glucose readings via text message, email or fax to family member, caregiver, physician or other designee • Integrated iglucometer with “iglucose inside” prototype complete; combines FDA-cleared glucometer technology with iglucose communication platform • Global market for glucometers and strips is forecast to reach $18B by 2015* • Three-year wireless communication agreement with AT&T • Wireless communication agreement with Rogers Wireless and CanCare to launch in Canada • Commitment to purchase a minimum of 28,000 units 5 *Source: Global Industry Analysts’ “Blood Glucose Meters and Strips: A Global Strategic Business Report,” October 2010

  6. iglucose Market Opportunity • Assumptions • Total market size equals 25 million diabetics in the U.S. • End user sale price of $90 device • Monthly subscription of $10 (annualized $120) • Strip sales - $0.05 per strip per reading, @ three readings/day • Assumptions • Timeline • 510(k) clearance received Nov. 2011 • Commercial launch expected in Q1 2012 Total annual market size for device sales 5% 10% 25% 50% Market penetration* Total annual market size for monthly subscription Total annual market size for strip sales 5% 10% 25% 50% Market penetration* 5% 10% 25% 50% Market penetration* 6 (Device sales and recurring revenue in $ millions on annual basis)

  7. Easy Check Breath Device • Easy Check™ breath glucose detection device, under development, is a non-invasive glucose detection system that measures acetone levels in a patient’s exhaled breath • The association between acetone levels in the breath and glucose is well documented • A handheld, battery-operated, portable, easy-to-use device that includes: • Advanced laser optical sensor, state-of-the-art microprocessor, patent-pending chemical sensors • The goal: patient exhales into the device to test glucose levels without the sample of blood presently required by existing glucometers • Utilizes single-use capsule containing proprietary sodium nitroprusside-based reagent that triggers a chemical reaction that is be measured and correlated to glucose levels • Preliminary lab tests reveal positive results within industry standards for glucometers as set by the National Committee of Clinical Laboratory Standards (currently Clinical and Laboratory Standards Institute – NCCL) and the International Organization for Standardization (ISO) • Could eliminate a patient’s need to prick his/her finger multiple times a day to get glucose readings • Patent pending 7

  8. Easy Check Market Opportunity • Assumptions • Total market size equals 25 million diabetics in the U.S. • End user sale price of $100 device • Replaceable single-use cartridge at $1.00 each • Five readings/day = over 1,800 readings/year • (Device sales and recurring revenue in $ millions on annual basis) • Timeline • Multi-variable/sensitivity testing through 2011 • Clinical studies to commence by YE 2011 through 2012 • Commercial prototype development in 2012 Annual recurring revenue @ one reading/day 5% 10% 25% 50% Market penetration* Annual recurring revenue @ five readings/day Total annual market size for device sales 5% 10% 25% 50% Market penetration* 5% 10% 25% 50% Market penetration* 8 *Does not include any assumption of growth in diabetic market.

  9. Glucose-Sensing Microchip (GlucoChip) • From our historical base with the original VeriChip – the shift from identification to diagnostic • In vivo glucose-sensing RFID microchip, the GlucoChip™, based on PositiveID’s Patent No. 7,125,382for Embedded Bio-Sensor System and Receptors’ patented CARA™ platform • Filed additional utility patent covering the interface between an RF powered resonant electromechanical drive and the fluids in the interstitial space of a patient for continuous detection of glucose levels in a patient • GlucoChip will lie completely under the skin to provide continuous glucose sensing; communicates glucose levels to an external scanner • Phase II development completed – successfully created a stable, reproducible glucose-sensing system and filed related patent • GlucoChip could negate the need for diabetics to prick their fingers multiple times per day: the “Holy Grail” of diabetic treatment • According to the American Diabetes Association, 25.8 million people in the U.S., or 8.3% of the population, have diabetes • Annual cost of treating diabetics in U.S. exceeds $110 billion; expected to triple in 25 years, reaching $336 billion* 9 * According to University of Chicago research published in Diabetes Care, November 2009

  10. GlucoChip Design Integrated sensor device design Components of the sensing/communication device SENSING SYSTEM SENSOR ELECTRONICS 10

  11. GlucoChip Market Opportunity • Assumptions • Total market size equals 25 million diabetics in the U.S. • End user sale price of $90 per device • Estimated one-year life of device • No sales of scanners or other revenue streams assumed • (Device sales in $ millions on annual basis) • Timeline • Sensing system completed in Q3 2011 • Membrane diffusion and biocompatibility testing Q4 2011-Q1 2012 • Sensor optimization and development of MEMS through mid-2012 • ASIC development and miniaturization mid-2012 - early 2013 • Animal testing and commercial partner Q1 2013 Total market size for device sales 5% 10% 25% 50% Market penetration* *Does not include any assumption of growth in diabetic market. 11

  12. MicroFluidic Systems • MFS specializes in the development and production of automated systems for a wide range of applications in the detection and processing of biological samples • Founded in 2001, MFS has received over $45 million in government and commercialcontracts in the last 10 years • Core technologies include sample prep, nucleic acid (DNA and RNA) and protein detection, automated fluidics and integrated systems • Focused on homeland security and pathogen diagnostic testing (field/clinical/ hospital) opportunities • Strong IP portfolio (29 U.S. Patents and Patents pending) and world-class scientific expertise • Acquired in May 2011; initial consideration of $1.4 million, primarily paid in stock. Additional earn-out of $7.0 million over four years based on revenue and earnings targets 12

  13. M-BAND Overview • M-BAND Integrated Pathogen Detection Systems • Bio-aerosol monitors with fully integrated systems with sample collection, processing and detection modules. Each module is fully functional and adaptable. MFS has implemented its own biological assays. • Key technologies: • Multiplexed assays • Networked, remotely operating • Cell lysis, nucleic acid purification • Homogeneous, Taqman PCR • Monoclonal antibody-based toxin detection • Product differentiators: • Rapid confirmation • High sensitivity • Fully autonomous operation • Complete integration of sample collection through toxin and pathogen detection 13

  14. MFS Market Opportunity • BioWatch – M-BAND • Total value of BioWatch opportunity is $3.1 billion over approximately five years • Acquisition of biodetectors and replenishment is expected to be 30-40% of total • We are one of only two potentially qualified biodetector systems suppliers • Net margins of 15-20% expected • Updated RFP expected by Q1 2012 • Other opportunities • MFS has submitted or in-process bids totaling $40 million, some of which are expected to be awarded in early 2012 • Opportunities include HHS, DHS, DTRA (Army) and NASA 14

  15. DragonFly Overview • Dragonfly Integrated Diagnostic Systems • Microfluidic cartridges for biological sample processing and detection including differential extraction cartridges, sample processing and amplification for biodefense applications, and clinical sample processing and detection. • Key technologies: • Rapid PCR Amplification • Fluorescent detection • Microfluidic Disposable Cartridges • Automated fluidics • Rapid cell lysis, nucleic acid purification • Product differentiators: • Fast results with high integrity • Affordable, disposable, portable • Automated and easy to use • Small operating footprint • Applications: • Environmental bacteria, e.g. E. coli • Clinical samples, e.g. HPV • Antibiotic-resistant bacteria, e.g. MRSA • Biothreat agents • Forensic applications 15

  16. Investment Highlights Unique, patent-pending technologies addressing large markets with significant unmet needs for new products Strong management team and outstanding scientists with proven track records FDA clearance for iglucose received in November 2011 – product launch expected by early 2012 Easy Check clinical studies commenced in Q4 2011 Significant BioWatch opportunity and strong pipeline of $40 million in potential new government contract opportunities Initial partnerships in place 16

  17. Balance Sheet 17

  18. Cap Structure 18

More Related